Tecalco-Cruz AC, Medina-Abreu KH, Oropeza-Martínez E, Zepeda-Cervantes J, Vázquez-Macías A, Macías-Silva M. Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression. World J Clin Oncol 2024; 15(2): 195-207 [PMID: 38455133 DOI: 10.5306/wjco.v15.i2.195]
Corresponding Author of This Article
Angeles C Tecalco-Cruz, PhD, Full Professor, Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, Colonia Del valle, San Lorenzo 290, Mexico 03100, Mexico. angeles.tecalco@uacm.edu.mx
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Feb 24, 2024; 15(2): 195-207 Published online Feb 24, 2024. doi: 10.5306/wjco.v15.i2.195
Deregulation of interferon-gamma receptor 1 expression and its implications for lung adenocarcinoma progression
Angeles C Tecalco-Cruz, Karen H Medina-Abreu, Enrique Oropeza-Martínez, Jesus Zepeda-Cervantes, Aleida Vázquez-Macías, Marina Macías-Silva
Angeles C Tecalco-Cruz, Karen H Medina-Abreu, Enrique Oropeza-Martínez, Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, CDMX 03100, Mexico
Jesus Zepeda-Cervantes, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, CDMX 04510, Mexico
Aleida Vázquez-Macías, Colegio de Ciencias y Humanidades, Universidad Autónoma de la Ciudad de México, CDMX 03100, Mexico
Marina Macías-Silva, Instituo de Fisiología Celular, Universidad Nacional Autónoma de México, CDMX 04510, Mexico
Author contributions: Tecalco-Cruz AC planned and participated in the research, organization of this article, and wrote the manuscript; Medina-Abreu KH, Oropeza-Martínez E, Zepeda-Cervantes J, Vázquez-Macías A, and Macías-Silva M participated in the research and wrote some parts of the manuscript; Tecalco-Cruz AC, Medina-Abreu KH, and Oropeza-Martínez E prepared some figures for this article; All authors revised the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Angeles C Tecalco-Cruz, PhD, Full Professor, Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, Colonia Del valle, San Lorenzo 290, Mexico 03100, Mexico. angeles.tecalco@uacm.edu.mx
Received: December 15, 2023 Peer-review started: December 15, 2023 First decision: December 22, 2023 Revised: January 5, 2024 Accepted: January 30, 2024 Article in press: January 30, 2024 Published online: February 24, 2024 Processing time: 66 Days and 18.4 Hours
Abstract
Interferon-gamma (IFN-γ) plays a dual role in cancer; it is both a pro- and an antitumorigenic cytokine, depending on the type of cancer. The deregulation of the IFN-γ canonic pathway is associated with several disorders, including vulnerability to viral infections, inflammation, and cancer progression. In particular, the interplay between lung adenocarcinoma (LUAD) and viral infections appears to exist in association with the deregulation of IFN-γ signaling. In this mini-review, we investigated the status of the IFN-γ signaling pathway and the expression level of its components in LUAD. Interestingly, a reduction in IFNGR1 expression seems to be associated with LUAD progression, affecting defenses against viruses such as severe acute respiratory syndrome coronavirus 2. In addition, alterations in the expression of IFNGR1 may inhibit the antiproliferative action of IFN-γ signaling in LUAD.
Core Tip: IFNGR1 is a transmembrane receptor required for interferon-gamma (IFN-γ) signaling. IFNGR1 expression is deregulated in lung adenocarcinoma, affecting IFN-γ signaling to promote cancer progression and reduce antiviral responses. Thus, the status of IFNGR1 expression may be critical in the detection of this cancer, and the restoration of its homeostasis may help control tumor progression and improve defense against viral infections.
